HK1199263A1 - Sulfated oligosaccharide derivatives - Google Patents

Sulfated oligosaccharide derivatives

Info

Publication number
HK1199263A1
HK1199263A1 HK14112830.3A HK14112830A HK1199263A1 HK 1199263 A1 HK1199263 A1 HK 1199263A1 HK 14112830 A HK14112830 A HK 14112830A HK 1199263 A1 HK1199263 A1 HK 1199263A1
Authority
HK
Hong Kong
Prior art keywords
oligosaccharide derivatives
sulfated oligosaccharide
sulfated
derivatives
oligosaccharide
Prior art date
Application number
HK14112830.3A
Other languages
English (en)
Chinese (zh)
Inventor
．費爾羅
．法爾威瑟
．卡洛麗
劉立功
Original Assignee
Progen Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004901103A external-priority patent/AU2004901103A0/en
Application filed by Progen Pharmaceuticals Ltd filed Critical Progen Pharmaceuticals Ltd
Publication of HK1199263A1 publication Critical patent/HK1199263A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK14112830.3A 2004-03-04 2007-12-19 Sulfated oligosaccharide derivatives HK1199263A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2004901103A AU2004901103A0 (en) 2004-03-04 Sulfated Oligosaccharide Derivatives

Publications (1)

Publication Number Publication Date
HK1199263A1 true HK1199263A1 (en) 2015-06-26

Family

ID=34916868

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112830.3A HK1199263A1 (en) 2004-03-04 2007-12-19 Sulfated oligosaccharide derivatives

Country Status (17)

Country Link
US (2) US7875592B2 (xx)
EP (1) EP1720889B1 (xx)
JP (1) JP5139797B2 (xx)
KR (1) KR101156273B1 (xx)
CN (3) CN104119404A (xx)
AU (1) AU2005219456B2 (xx)
BR (1) BRPI0508144A (xx)
CA (1) CA2557989C (xx)
ES (1) ES2531880T3 (xx)
HK (1) HK1199263A1 (xx)
IL (1) IL177870A (xx)
MX (1) MXPA06010049A (xx)
NO (1) NO338461B1 (xx)
RU (1) RU2392281C2 (xx)
TW (1) TWI426080B (xx)
WO (1) WO2005085264A1 (xx)
ZA (1) ZA200607057B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531880T3 (es) * 2004-03-04 2015-03-20 Progen Pharmaceuticals Limited Derivados de oligosacáridos sulfatados
AU2006228991A1 (en) * 2005-04-01 2006-10-05 Michael A. Djordjevic Modulating angiogenesis with Nod factors such as glucosamine oligosaccharides
US8828952B2 (en) * 2007-10-16 2014-09-09 Progen Pharmaceuticals Limited Sulfated oligosaccharide derivatives
US20100048638A1 (en) * 2008-07-01 2010-02-25 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
EP2149580A1 (en) 2008-07-15 2010-02-03 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Mimetics of sulfated oligosaccharides
CN101591401A (zh) * 2009-02-27 2009-12-02 江南大学 一种制备高活性低分子量肝素的方法
JP5701498B2 (ja) * 2009-12-01 2015-04-15 公益財団法人微生物化学研究会 炎症性細胞からのヘパラナーゼの放出抑制剤、抗炎症剤、及び薬用組成物
CN107362168A (zh) * 2011-06-09 2017-11-21 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物
JP6502374B2 (ja) 2014-03-13 2019-04-17 ウニヴェルズィテート バーゼル ミエリン関連糖タンパク質に対するＩｇＭ抗体に結合する炭水化物リガンド
CN105017341B (zh) * 2014-04-22 2018-05-15 华东师范大学 硫酸化岩藻-半乳四糖及其制备方法和应用
CN105001278B (zh) * 2015-06-19 2018-07-06 天津红日药业股份有限公司 一种磺达肝癸钠二糖中间体片段的合成方法
CN104876979B (zh) * 2015-06-19 2018-10-09 天津红日药业股份有限公司 一种具有抗Xa因子活性的磺酸化五糖化合物
WO2017046172A1 (en) 2015-09-16 2017-03-23 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
JP2016199579A (ja) * 2016-07-08 2016-12-01 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
CN109069523B (zh) * 2016-12-10 2022-05-06 扬州蓝色生物医药科技有限公司 甘露寡聚糖类化合物及其作为抗rna病毒药物的应用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CA3046997A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
JP2020502149A (ja) 2016-12-15 2020-01-23 プロゲン・ピージー５００・シリーズ・プロプライエタリー・リミテッドＰｒｏｇｅｎ Ｐｇ５００ Ｓｅｒｉｅｓ Ｐｔｙ Ｌｔｄ 組成物およびその使用
US10842804B2 (en) * 2017-03-01 2020-11-24 Medigen Biotechnology Corporation Muparfostat for use in treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection
KR102377358B1 (ko) 2017-10-16 2022-03-23 삼성전자주식회사 반도체 메모리 소자 및 그 제조 방법
US11628179B2 (en) 2017-12-15 2023-04-18 The Australian National University Compounds for treating and preventing extracellular histone mediated pathologies
JP6619830B2 (ja) * 2018-02-22 2019-12-11 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
CN109762032A (zh) * 2019-01-16 2019-05-17 天津科技大学 一种磺酸化路易斯x三糖及其合成方法和应用
BR112021016812A2 (pt) * 2019-02-25 2021-11-16 Univ Griffith Compostos para tratar e prevenir complicações associadas a net
CN116813675B (zh) * 2023-08-23 2023-11-24 北京远大九和药业有限公司 一种化合物晶型及其制备、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338092A1 (en) 1987-10-30 1989-10-25 Chugai Seiyaku Kabushiki Kaisha Anti-hiv agent
US5739115A (en) * 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
JPH09503510A (ja) * 1993-10-07 1997-04-08 グリコメド・インコーポレイテッド ヘパリン様特性を有する高硫酸化マルトオリゴ糖
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
JPH09183789A (ja) * 1995-10-31 1997-07-15 Sanwa Kagaku Kenkyusho Co Ltd 新規な硫酸化及び燐酸化糖誘導体、その製法及び用途
AUPO556297A0 (en) 1997-03-11 1997-04-10 Australian National University, The Sulfated oligosaccharides having anticoagulant/ antithrombotic activity
IL126893A (en) * 1997-11-19 2003-05-29 Akzo Nobel Nv Sulfated pentasaccharide derivatives and pharmaceutical compositions containing them
CN1450075A (zh) * 2002-04-11 2003-10-22 中国科学院生态环境研究中心 一类寡糖及其硫酸化产物和它们的制备方法及含该寡糖的药物组合物
ES2531880T3 (es) * 2004-03-04 2015-03-20 Progen Pharmaceuticals Limited Derivados de oligosacáridos sulfatados

Also Published As

Publication number Publication date
CA2557989C (en) 2013-04-23
AU2005219456A1 (en) 2005-09-15
CN103788141B (zh) 2016-08-17
IL177870A0 (en) 2006-12-31
NO338461B1 (no) 2016-08-15
KR101156273B1 (ko) 2012-06-13
ES2531880T3 (es) 2015-03-20
WO2005085264A1 (en) 2005-09-15
RU2392281C2 (ru) 2010-06-20
EP1720889A4 (en) 2008-03-19
CN103788141A (zh) 2014-05-14
CN104119404A (zh) 2014-10-29
JP5139797B2 (ja) 2013-02-06
RU2006134972A (ru) 2008-04-10
TW200602351A (en) 2006-01-16
CA2557989A1 (en) 2005-09-15
NO20064489L (no) 2006-11-27
US20110130354A1 (en) 2011-06-02
IL177870A (en) 2011-08-31
AU2005219456B2 (en) 2011-04-07
BRPI0508144A (pt) 2007-07-24
EP1720889A1 (en) 2006-11-15
CN1989146A (zh) 2007-06-27
TWI426080B (zh) 2014-02-11
ZA200607057B (en) 2008-04-30
US20070185037A1 (en) 2007-08-09
US8173606B2 (en) 2012-05-08
KR20070007815A (ko) 2007-01-16
JP2007526257A (ja) 2007-09-13
US7875592B2 (en) 2011-01-25
MXPA06010049A (es) 2007-04-10
EP1720889B1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
ZA200607057B (en) Sulfated oligosaccharide derivatives
HK1209648A1 (en) Novel sulfated oligosaccharide derivatives
TWI369356B (en) Tetrahydropyridoindole derivatives
HUS2000022I1 (hu) Tiglien-3-on származékok
IL180481A0 (en) Aryl-pyridine derivatives
EP1878727A4 (en) 2-AMINOQUINAZOLINE DERIVATIVES
ZA200610102B (en) Pyrrazolo-pyrimidine derivatives
IL192092A0 (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
IL185674A0 (en) 1-benzylindole-2-carboxamide derivatives
ZA200703172B (en) Imidazo-benzodiazepine derivatives
IL192235A0 (en) Aryl-isoxazol-4-yl-imidazole derivatives
HK1100002A1 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
HK1100775A1 (en) 4-Amino-5-cyanopyrimidine derivatives
GB0414272D0 (en) OsK1 derivatives
IL191138A0 (en) Pyrazoloisoquinoline derivatives
GB0511410D0 (en) Benzotrizepinone derivatives
IL182001A0 (en) 2-acylaminothiazole derivatives
AU2004901103A0 (en) Sulfated Oligosaccharide Derivatives
HU0401553D0 (en) Sulfated oligosaccharides
GB0422397D0 (en) 3-Cyano-Quinoline derivatives
GB0405905D0 (en) Azaquinazoline derivatives
GB0500900D0 (en) Azaquinazoline derivatives